HC Wainwright & Co. analyst Mitchell Kapoor initiates coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral rating and announces Price Target of $8.
HC Wainwright & Co. Initiates Coverage On Kyverna Therapeutics With Neutral Rating, Announces Price Target of $8
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.